DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Indoco Remedies Limited — Outcome of Board Meeting

NSE 59 min ago·27 Oct 2026, 7:17 am

Indoco Remedies

Indoco Remedies Limited has informed the stock exchanges about the financial results for the period ending September 30, 2026. This filing is a routine corporate disclosure required for listed companies to keep the market updated on their performance.

For investors, this update provides the first look at the company's operational health and financial standing during the third quarter of the fiscal year. It is a key indicator of how the company is managing its business and generating revenue.

Investors should focus on the company's revenue growth, profit margins, and any commentary from management regarding future outlook. Monitoring the stock's reaction to this news will help gauge market sentiment towards the company's performance.